Mount Sinai Heart announced on Oct. 31, 2022, that renowned cardiologist and Cardiometabolic Health Congress (CMHC) Senior Planning Committee member Deepak L. Bhatt, MD, MPH, has been named their incoming director.
Dr. Bhatt will lead the educational, research, and clinical cardiovascular work of the Icahn School of Medicine at Mount Sinai and the Mount Sinai Health System beginning Thursday, Dec. 1, 2022. He will also serve as the Dr. Valentin Fuster Professor of Cardiovascular Medicine, the first physician to hold this endowed professorship.
After dedicating the last 28 years to building one of the world’s leading cardiovascular centers, Valentin Fuster, MD, PhD, who has been director of Mount Sinai Heart since its founding in 2006, will become the new president of Mount Sinai Heart as of Sunday, January 1, 2023.
In this newly created position, Dr. Fuster will transition from the day-to-day administrative leadership of Mount Sinai Heart into the new advisory position. Dr. Fuster will continue in his roles as Physician-in-Chief of The Mount Sinai Hospital and as the Richard Gorlin, MD/Heart Research Foundation Professor at the Icahn School of Medicine at Mount Sinai.
“Dr. Fuster is a luminary in cardiovascular clinical care, education, and research, whose decades of service to Mount Sinai have elevated the entire Health System,” said Margaret Pastuszko, MBA, President and Chief Operating Officer of the Mount Sinai Health System.
Dr. Bhatt comes to Mount Sinai Heart from Brigham and Women’s Hospital Heart and Vascular Center, where he has been executive director of Interventional Cardiovascular Programs, and Harvard Medical School, where he was professor of medicine. Previously, he served as the chief of Cardiology at VA Boston Healthcare from 2008-2013, and prior to that held a variety of leadership positions at Cleveland Clinic.
“A worthy successor to Dr. Fuster would be almost impossible to find, but Deepak Bhatt is the rare individual who can actually meet that standard. Mount Sinai’s legacy of world-leading cardiology will continue under his leadership,” said Kenneth L. Davis, MD, Chief Executive Officer of Mount Sinai Health System.
Dr. Bhatt is highly recognized for his significant breakthroughs in the fields of interventional cardiology, heart disease prevention, vascular medicine, and heart failure. He led a trial that demonstrated the benefit of a potent intravenous antithrombotic drug during stenting, including significant reductions in stent clotting, which led to its Food and Drug Administration (FDA) and European Medicines Agency approvals.
“Deepak Bhatt is one of the most outstanding researchers and clinicians in cardiology today,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and President for Academic Affairs of the Mount Sinai Health System. “In recruiting him to Mount Sinai, what was very important to me was his ambition to elevate Mount Sinai Heart— one of the world’s top cardiovascular clinical and research centers — to even greater heights. He is a worthy successor to Valentin Fuster. To me, there is no higher praise.”
Bhatt’s professional achievements
Not only does Dr. Bhatt serve as editor for several peer-reviewed medical journals, but he has also authored or co-authored more than 1,900 publications. He has received numerous accolades for his research, mentorship, and clinical achievements.
Notably, he’s been the recipient of the: 2016 Research Mentor Award from Brigham and Women’s Hospital Department of Medicine; 2017 Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology from Brigham and Women’s Hospital; 2018 American College of Cardiology’s Distinguished Mentor Award; 2019 American Heart Association’s Distinguished Scientist Award; 2021 National Lipid Association’s Honorary Lifetime Membership Award; and 2022 Society of Cardiovascular Angiography and Intervention’s Master designation.
Dr. Bhatt was instrumental in the first FDA approval of an omega-3 fatty acid prescription medication to reduce cardiovascular risk among patients with elevated triglyceride levels already treated with statins. He also led the first trial to show a significant benefit of SGLT2 inhibition in treating patients who have heart failure despite having normal heart muscle function, a major milestone in medicine. His work to improve clinicians’ understanding of patients with diabetes and obesity who have cardiovascular disease has resulted in better treatment strategies.
“I am very excited to take on this leadership role at Mount Sinai Heart, one of the best cardiovascular centers in the world for clinical care, research, and education. I am humbled to be named the Dr. Valentin Fuster Professor – it is a singular honor in the world of medicine that is unmatched,” said Dr. Bhatt.
More about Mount Sinai Heart
Mount Sinai Heart is among the top six hospitals in the nation for cardiology and cardiac surgery, according to U.S. News & World Report. According to Newsweek, Mount Sinai Heart is ranked first in New York and fourth globally in their “The World’s Best Specialized Hospitals” list.
Mount Sinai Health System is one of the largest academic medical systems in the New York area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education.
Through its clinical and research efforts, Mount Sinai advances health through the discovery and application of new scientific learning and knowledge; the development of safer, more effective treatments; the education and training of the next generation of medical leaders and innovators; and the support of local communities by delivering high-quality care.
“The Mount Sinai Health System will be enriched by the outstanding recruitment of Dr. Deepak Bhatt, one of the most brilliant clinicians and academicians in the cardiovascular field today,” said Dr. Fuster.